A model was developed in dogs to determine the impact of oral enrofloxacin administration on the indigenous coliform population in the gastrointestinal tract and subsequent disposition to colonization by a strain of multidrug-resistant Escherichia coli (MDREC). Dogs given a daily oral dose of 5 mg enrofloxacin kg−1 for 21 consecutive days showed a significant decline in faecal coliforms to levels below detectable limits by 72 h of administration. Subsequently, faecal coliforms remained suppressed throughout the period of enrofloxacin dosing. Upon termination of antibiotic administration, the number of excreted faecal coliforms slowly returned over an 8-day period, to levels comparable to those seen prior to antibiotic treatment. Enrofloxacin-treated dogs were more effectively colonized by MDREC, evidenced by a significantly increased count of MDREC in the faeces (7.1 ± 1.5 log10 g−1) compared with non-antibiotic-treated dogs (5.2 ± 1.2; P = 0.003). Furthermore, antibiotic treatment also sustained a significantly longer period of MDREC excretion in the faeces (26.8 ± 10.5 days) compared with animals not treated with enrofloxacin (8.5 ± 5.4 days; P = 0.0215). These results confirm the importance of sustained delivery of an antimicrobial agent to maintain and expand the colonization potential of drug-resistant bacteria in vivo, achieved in part by reducing the competing commensal coliforms in the gastrointestinal tract to below detectable levels in the faeces. Without in vivo antimicrobial selection pressure, commensal coliforms dominated the gastrointestinal tract at the expense of the MDREC population. Conceivably, the model developed could be used to test the efficacy of novel non-antibiotic strategies aimed at monitoring and controlling gastrointestinal colonization by multidrug-resistant members of the Enterobacteriaceae that cause nosocomial infections.
BlochN.,
Sidjabat-TambunanH.,
TrattT.,
BensinkJ.,
LeaK.,
FrostA. J.1996; The enumeration of coliforms and E.coli on naturally contaminated beef: a comparison of the PetrifilmTM method with the Australian standard. Meat Sci 43:187–193[CrossRef]
BoerlinP.,
EugsterS.,
GaschenF.,
StraubR.,
SchawalderP.2001; Transmission of opportunistic pathogens in a veterinary teaching hospital. Vet Microbiol 82:347–359[CrossRef]
CookeC. L.,
SingerR. S.,
JangS. S.,
HirshD. C.2002; Enrofloxacin resistance in Escherichia coli isolated from dogs with urinary tract infections. J Am Vet Med Assoc 220:190–192[CrossRef]
EdlundC.,
NordC. E.2000; Effect on the human normal microflora of oral antibiotics for treatment of urinary tract infections. J Antimicrob Chemother 46 (Suppl. 1):41–48[CrossRef]
FériaC.,
FerreiraE.,
CorreiaJ. D.,
GoncalvesJ.,
CanicaM.2002; Patterns and mechanisms of resistance to β-lactams and β-lactamase inhibitors in uropathogenic Escherichia coli isolated from dogs in Portugal. J Antimicrob Chemother 49:77–85[CrossRef]
GarauJ.,
XercavinsM.,
Rodríguez-CarballeiraM.,
Gómez-VeraJ. R.,
CollI.,
VidalD.,
LlovetT.,
Ruíz-BremónA.1999; Emergence and dissemination of quinolone-resistant Escherichia coli in the community. Antimicrob Agents Chemother 43:2736–2741
JohnsonJ. R.,
StellA. L.,
DelavariP.2001; Canine feces as a reservoir of extraintestinal pathogenic Escherichia coli
. Infect Immun 69:1306–1314[CrossRef]
NCCLS1998Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals . Proposed standard. NCCLS document M31-A Villanova, PA: National Committee for Clinical Laboratory Standards;
ReevesD. S.1986; The effect of quinolone antibacterials on the gastrointestinal flora compared with that of other antibacterials. J Antimicrob Chemother 18 (Suppl. D):89–102
RichardP.,
DelangleM. H.,
RaffiF.,
EspazeE.,
RichetH.2001; Impact of fluoroquinolone administration on the emergence of fluoroquinolone-resistant gram-negative bacilli from gastrointestinal flora. Clin Infect Dis 32:162–166[CrossRef]
RuppM. E.,
FeyP. D.2003; Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae : considerations for diagnosis, prevention and drug treatment. Drugs 63:353–365[CrossRef]
TeshagerT.,
DominguezL.,
MorenzoM. A.,
SaénzY.,
TorresC.,
CardenosaS.2000; Isolation of an SHV-12 β-lactamase-producing Escherichia coli strain from a dog with recurrent urinary tract infections. Antimicrob Agents Chemother 44:3483–3484[CrossRef]
TownsendK.,
StokesH.,
MossS.,
TrottD.2002; Multi-drug resistant Escherichia coli in a veterinary teaching hospital: mechanisms of resistance. In Abstracts of the 102nd General Meeting of the American Society for Microbiology p A–2613 Washington, DC: American Society for Microbiology;
van der WaaijD.,
NordC. E.2000; Development and persistence of multi-resistance to antibiotics in bacteria; an analysis and a new approach to this urgent problem. Int J Antimicrob Agents 16:191–197[CrossRef]
WarrenA.,
TownsendK.,
KingT.,
MossS.,
O'BoyleD.,
YatesR.,
TrottD. J.2001; Multi-drug resistant Escherichia coli with extended-spectrum β-lactamase activity and fluoroquinolone resistance isolated from clinical infections in dogs. Aust Vet J 79:621–623[CrossRef]